TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2141082
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 1% etidocaine applied to the banded portion of each fallopian tube after laparoscopic tubal ligation
Study: 363995
Drug: Placebo (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.20 ml/kg)
Study: 31331574
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a + sesame oil (0.5 ml/kg/day for 6 months)
Study: 31331574
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (30 μg/week)
Study: 15966502
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg (CEE/MPA)
Study: 10496359
Drug: CMF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (cyclophosphamide 600 mg m(‐2) day 1 and 8 i.v., 5‐fluorouracil 600 mg m(‐2) day 1 and 8 i.v., methotrexate 40 mg m(‐2) day 1 and 8 i.v., monthly for 6 cycles)
Study: 10496359
Drug: MM (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MM (methotrexate 30 mg m(‐2), mitoxantrone 6.5 mg m(‐2), both i.v. day 1 3‐weekly for 8 cycles)
Study: 7034164
Drug: Trimipramine, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine, 25 mg at night + antacids 20 ml 1 and 3 h after meals
Study: 7034164
Drug: Cimetidine, 400
Normalized name: Cimetidine, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 400 mg at night + antacids 20 ml 1 and 3 h after meals
Study: 7034164
Drug: Cimetidine, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 1000 mg/day + antacids 20 ml 1 and 3 h after meals
Study: 25362864
Drug: DA-1229 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-1229 2.5 mg
Study: 25362864
Drug: DA-1229 5
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-1229 5 mg
Study: 25362864
Drug: DA-1229 10
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-1229 10 mg
Study: 25362864
Drug: DA-1229 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-1229 (all doses)
Study: 12204314
Drug: Milnacipran (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (50 mg twice daily, n=53)
Study: 12204314
Drug: Imipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (75 mg twice daily, n=56)
Study: 9718229
Drug: Metrifonate (AChE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (AChE inhibitor)
Study: 7648385
Drug: Placebo (plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (plus as-needed albuterol)
Study: 692379
Drug: Metergoline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline (4 mg)
Study: 692379
Drug: Methysergide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methysergide (3 mg)
Study: 23465062
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone followed after 48 hours by 400 μg oral misoprostol (Study One)
Study: 23465062
Drug: Mifepristone followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone followed after 24 hours by 400 μg sublingual misoprostol (Study Two)
Study: 21299448
Drug: Tailored doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored doses of FEC chemotherapy
Study: 21299448
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of FEC chemotherapy
Study: 19922552
Drug: Adjunctive risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adjunctive risperidone long-acting therapy (RLAT) plus treatment-as-usual (TAU) (n = 65)
Study: 19922552
Drug: Adjunctive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive placebo injection plus treatment-as-usual (TAU) (n = 59)
Study: 17121317
Drug: Myoinositol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoinositol (4 g daily) plus folic acid (400 microg daily)
Study: 3318442
Drug: S-adenosylmethionine (SAMe)
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosylmethionine (SAMe) 1,200 mg daily
Study: 29069400
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg LCB01-0371 once or twice daily for 21 days
Study: 29069400
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg LCB01-0371 twice daily for 21 days
Study: 27017611
Drug: Febuxostat (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (60 mg/day)
Study: 27017611
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 or 200 mg/day)
Study: 18621575
Drug: Episodic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic treatment with famciclovir (125 mg twice daily for 5 days)
Study: 18621575
Drug: Suppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive treatment with famciclovir (250 mg twice daily)
Study: 12631176
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine solution (CHX)
Study: 9524008
Drug: Metoprolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (mean daily dose: 184 mg)
Study: 9524008
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (IS-5-MN + Metoprolol)
Study: 9524008
Drug: Isosorbide-5-mononitrate (IS-5-MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5-MN) (mean daily dose: 33 mg)
Study: 7974024
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy at 400 mg or 800 mg
Study: 7974024
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy at 800 mg
Study: 7974024
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy at 400 mg
Study: 3296967
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy
Study: 7974024
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy (400 mg and 800 mg)
Study: 2564243
Drug: Aminophylline, 110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline, 110 mg
Study: 30650270
Drug: Liujin Runzao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liujin Runzao Concentrated Decoction (LRCD), 30 mL twice per day for 4 weeks (two courses).
Study: 30650270
Drug: Standard therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy: Radix Paeoniae alba total glycosides 600 mg, twice per day.
Study: 30650270
Drug: Liujin Runzao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liujin Runzao Concentrated Decoction (LRCD) + Standard therapy.
Study: 30650270
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Standard therapy only).
Study: 30650270
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (LRCD + Standard therapy).
Study: 22359978
Drug: Metformin (3-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (3-month treatment with oral hormonal contraceptives: ethynil estradiol 35 microg plus cyproterone acetate 2 mg)
Study: 22359978
Drug: Rosiglitazone (3-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (3-month treatment with oral hormonal contraceptives: ethynil estradiol 35 microg plus cyproterone acetate 2 mg)
Study: 11329232
Drug: Dose‐intensive intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose‐intensive intravenous melphalan and autologous blood stem‐cell transplantation
Study: 9499666
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or combined therapy for stage II BDHD
Study: 3597148
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravesical misonidazole (MISO)
Study: 25733633
Drug: EGCG (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (600 mg/d)
Study: 23944044
Drug: Zhennaoning capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhennaoning capsules
Study: 19462303
Drug: Gamma-Hydroxybutyric acid
Normalized name: gamma-Hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-Hydroxybutyric acid (GHB) administered intravenously, initially 30 mg/kg body weight (BW) followed by 15 mg/kg BW.
Study: 19462303
Drug: Clomethiazole (CLO)
Normalized name: Clomethiazole
DrugBank: Clomethiazole (DB06470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomethiazole (CLO) given orally to 12 patients in a dosage of 250 mg every 4 hours as a liquid.
Study: 15274672
Drug: Uncoated immediate
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uncoated immediate release tablets
Study: 9587285
Drug: 3.6 ml
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 ml of 2% lidocaine with 1:50,000
Study: 9587285
Drug: 3.6 ml
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 ml of 2% lidocaine with 1:80,000
Study: 9587285
Drug: 3.6 ml
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 ml of 2% lidocaine with 1:100,000
Study: 9587285
Drug: 1.8 ml
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 ml of 2% lidocaine with 1:50,000
Study: 9587285
Drug: 1.8 ml
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 ml of 2% lidocaine with 1:80,000
Study: 9587285
Drug: 1.8 ml
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 ml of 2% lidocaine with 1:100,000
Study: 8390795
Drug: Daily antimony
Normalized name: antimony
DrugBank: Antimony (DB13110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antimony plus interferon-gamma (IFN-gamma) every other day (n = 10)
Study: 8390795
Drug: Daily pentavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pentavalent antimony (n = 14)
Study: 19687359
Drug: Propranolol 20
Normalized name: propranolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 20 mg
Study: 27051354
Drug: DHA-enriched beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched beverage (1.16 g DHA/day) for 8 weeks
Study: 20668549
Drug: EchiTAb Plus-ICP
Approvals — FDA: no, EMA: no, PMDA: no
Description: EchiTAb Plus-ICP (ET-Plus) - initial dose 3 vials
Study: 20668549
Drug: EchiTAb G
Approvals — FDA: no, EMA: no, PMDA: no
Description: EchiTAb G (ET-G) - initial dose 1 vial
Study: 20668549
Drug: EchiTAb G
Approvals — FDA: no, EMA: no, PMDA: no
Description: EchiTAb G (ET-G)
Study: 11801808
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ex‐MLT
Study: 11801808
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg ex‐MLT
Study: 11801808
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg ex‐MLT
Study: 8112231
Drug: Allopurinol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (150 mg daily for children < 20 kg; 300 mg daily for others)
Study: 31453617
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (600 mg per day)
Study: 31453617
Drug: Placebo (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (600 mg cellulose per day)
Study: 25112175
Drug: L-tryptophan, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan, 1 g orally three times a day for up to 3 days postoperatively
Study: 22566583
Drug: TEAMcare intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TEAMcare intervention (multicondition collaborative treatment program)
Study: 17883296
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin 100 mg administered 2 hours prior to ERCP
Study: 17883296
Drug: Rectal glycerin
Normalized name: glycerin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal glycerin (control group)
Study: 14597376
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine in children without older siblings attending day-care at 24 months
Study: 10561226
Drug: IFNalpha therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNalpha therapy
Study: 10561226
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (CHT)
Study: 8741040
Drug: Pentoxifylline (PTXF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTXF) 5 mg/kg per hour for 6 hours for 3 successive days
Study: 7116299
Drug: Oral melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral melphalan (0.15 mg/kg/day for seven days, followed by 0.05 mg/kg/day after recovery from the nadir of the leukocytes) + Prednisone (0.8 mg/kg for the first two weeks, tapering over six weeks)
Study: 7116299
Drug: BCNU (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU (150 mg/m2 intravenously every six weeks) + Prednisone (0.8 mg/kg for the first two weeks, tapering over six weeks)
Study: 7116299
Drug: CCNU (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCNU (100 mg/m2 orally every six weeks) + Prednisone (0.8 mg/kg for the first two weeks, tapering over six weeks)
Study: 7116299
Drug: Vincristine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (1 mg/m2) + Prednisone (0.6 mg/kg for seven days) every two months (added at week 22)
Study: 7116299
Drug: Good-risk patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good-risk patients treated with oral melphalan
Study: 29048765
Drug: Ageratum conyzoides
Normalized name: Vincetoxicum atratum root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ageratum conyzoides extract at a dose of 250 mg/d, q.d. for 12 weeks
Study: 24633440
Drug: Transcricoid lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcricoid lignocaine injection
Study: 24439313
Drug: Chemotherapy (multidrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (multidrug for at least four courses recommended)
Study: 20021401
Drug: Low frequency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low frequency transcutaneous sensory nerve stimulation (LF‐SNS) for 5 minutes, twice daily for up to 12 weeks
Study: 21179755
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement designed for high altitude
Study: 21179755
Drug: Stir-fried flour
Normalized name: stiripentol
DrugBank: Stiripentol (DB09118)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Stir-fried flour supplement (Control)
Study: 13680141
Drug: Alendronate (ALN),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (ALN), 10 mg daily
Study: 13680141
Drug: Alfacalcidol (AC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (AC), 1 microg daily
Study: 7596131
Drug: DL-nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-nebivolol 5 mg once daily for 4 weeks
Study: 7596131
Drug: D-nebivolol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-nebivolol 2.5 mg once daily for 4 weeks
Study: 2248813
Drug: metoclopramide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 0.1 mg kg‐1
Study: 2248813
Drug: ranitidine 2
Normalized name: ranitidine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 2 mg kg‐1
Study: 2248813
Drug: metoclopramide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 0.1 mg kg‐1 with ranitidine 2 mg kg‐1
Study: 6989292
Drug: (+)-ketamine (PK),
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-ketamine (PK), 1 mg/kg
Study: 6989292
Drug: (−)-ketamine (MK),
Approvals — FDA: no, EMA: no, PMDA: no
Description: (−)-ketamine (MK), 3 mg/kg
Study: 6989292
Drug: racemic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: racemic ketamine (RK), 2 mg/kg
Study: 31206433
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (2-3 µg·kg) administered approximately 1 hour before MRI
Study: 30621614
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (titrated doses of 20 to 60 μg following a 3 h on + 1 h off regimen up to a maximum of 24 h)
Study: 30621614
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (25 μg every 4 h up to a maximum of 24 h)
Study: 30621614
Drug: Vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal dinoprostone (10 mg via controlled-release vaginal insert for up to 24 h)
Study: 28656353
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume with PEEP (TV, 5-7 ml/kg; PEEP, 4-6 cmH2O)
Study: 28656353
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (TV, 8-10 ml/kg; PEEP, 0 cmH2O)
Study: 24491348
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly structured exercise training (ET) for 12 weeks
Study: 16404566
Drug: Direct radiography
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct radiography (DR) at 50% dose
Study: 16404566
Drug: Computed radiography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computed radiography (CR) at regular dose
Study: 16404566
Drug: Direct radiography
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct radiography (DR) at regular dose
Study: 16404566
Drug: Direct radiography
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct radiography (DR) at reduced dose
Study: 28752433
Drug: ANF-RHO (5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANF-RHO (5-50 μg/kg)
Study: 28752433
Drug: ANF-RHO (5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANF-RHO (5-30 μg/kg)
Study: 28752433
Drug: ANF-RHO (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANF-RHO (50 μg/kg)
Study: 28752433
Drug: Pegfilgrastim (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (6 mg, equivalent to 80-100 μg/kg)
Study: 28101914
Drug: Low cortisol
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low cortisol (300 ng mL-1)
Study: 28101914
Drug: High cortisol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cortisol (1,000 ng mL-1)
Study: 28101914
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 ng mL-1)
Study: 25252663
Drug: Passive tactile
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive tactile stimulation (two daily sessions of 30 minutes each for six months)
Study: 20181361
Drug: LI160 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI160 (600 mg)
Study: 8347969
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection into the epidural space
Study: 3519043
Drug: Urapidil 60
Normalized name: urapidil 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 60 mg
Study: 3519043
Drug: Urapidil 90
Normalized name: urapidil 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 90 mg
Study: 3519043
Drug: Urapidil 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 120 mg
Study: 29898059
Drug: Ketoprofen 200
Normalized name: ketoprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 200 mg + Omeprazole 20 mg (once daily - q.d.)
Study: 29898059
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg (twice daily - b.i.d.)
Study: 19459752
Drug: Camel milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camel milk (500 mL daily)
Study: 19459752
Drug: Usual management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual management (diet, exercise, and insulin)
Study: 17257536
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (1.0 ml)
Study: 17257536
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (1.0 ml)
Study: 11666117
Drug: TTFCA (tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA (tablets, 60 mg, twice daily for 8 weeks)
Study: 9840297
Drug: Enzyme-linked immunosorbent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-linked immunosorbent assay (ELISA) for detecting serum anti-H. pylori immunoglobulin G antibodies
Study: 31784559
Drug: L-DOPA treatment
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA treatment
Study: 23707162
Drug: Attenuated Listeria
Normalized name: Live-attenuated listeria monocytogenes encoding egfrviii-mesothelin vaccine jnj-64041757
DrugBank: Pemlimogene merolisbac (DB16286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated Listeria monocytogenes vaccine strain with cholera toxin adjuvant
Study: 20008225
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy as post-remission therapy